A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
Active, not recruiting · Phase 2 · NCT06718101
Conditions: Atopic Dermatitis
At a glance
- Research payments reported, 2025
- $1.0M
- U.S. investigators named
- 18
- Sites paid
- 18
- Planned or actual enrollment
- 83
About the trial
- Sponsor
- AbbVie
- Tested
- Lutikizumab (drug), Placebo (drug)
- Dates
- Started 2024-12-19; completion 2027-05
- Results posted
- Not yet
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluate the clinical efficacy and safety of single therapies and/or combination therapies for moderate to severe AD through multiple substudies. This study will consist of multiple substudies. Substudy 1 will have a randomized, open-label period 1 followed by a lutikizumab treatment period 2 enrolling 80 participants at a 1 to 1 ratio. In Substudy 1, participants will receive subcutaneous (SC) injections of lutikizumab or matching placebo every other week for 16 weeks followed by an additional 32 weeks of SC injections of lutikizumab every other we…
From ClinicalTrials.gov, last updated 2026-08-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $1.0M in research payments for this study in 2025 (105 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Navid Ezra, M.D. Dermatology · Thousand Oaks, CA
- Raja Sivamani, M.D., M.S., A.H.E. Dermatology · Sacramento, CA
- Howard L. Sofen, M.D. Dermatology · Los Angeles, CA
- Jeffrey S. Rumbyrt, M. D. Allergy & Immunology · Lakewood, CO
- Sandro Bacchelli, MD Family Medicine · Hollywood, FL
- Francis A. Caban, M.D. Dermatology · Brandon, FL
- Kristin Haushalter, MD Dermatology · Miami, FL
- Ann M. Reed, D.O. Dermatology · Boca Raton, FL
- Michael Bukhalo, MD Dermatology · Rolling Meadows, IL
- Robert J. Szalewski, M.D. Allergy & Immunology · Lincoln, NE
- Michael C. Cameron Dermatology · New York, NY
- Phoebe Rich, MD Specialist · Portland, OR
- Kathleen P. Gordon, DO Internal Medicine · Johnston, RI
- Richard L. Beasley, MD Internal Medicine · Rapid City, SD
- Jennifer D. Holman, MD Dermatology · Tyler, TX
- William C. Howland III, MD Allergy & Immunology · Austin, TX
- Patricia C. Lee, M.D. Dermatology · Webster, TX
- Vandana Madkan, MD Dermatology · Sugar Land, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Caban Health LLC $195,819
- Michael Bukhalo MD Sc $152,387
- Odrc Enterprises LLC $103,091
- Equity Medical LLC $89,300
- Skin Care Research Inc $74,488
- Encore Medical Research of Weston $67,704
- Rlb MD PC $65,333
- Research Associates of S Flo LLC $54,216
- Western States Clinical $51,623
- Clinical PArtners LLC $34,865
- Integrative Skin Science $30,591
- Clinical Trials Research Institute $21,166
- Center for Clinical Studies LTD LLP $19,013
- Dermatology Research Associates Inc $14,098
- Oliver Street 501 (a) Inc $12,079
- Gsr Enterprises Inc $11,279
- Complete Dermatology PLLC $10,579
- Howland Allergy & Asthma PLLC $10,110
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.